Generate Biomedicines, Inc. (GENB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Generate Biomedicines, Inc. (GENB) closed at USD 12.52 on 2026-10-14, a change of -1 % over the past year, with a market capitalization of USD 1.68B.

Generate Biomedicines, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Generate Biomedicines, Inc. key figures

Previous close

USD 12.52 (2026-10-14)

1-year change

-1 %

Market cap

USD 1.68B

Enterprise value

USD 1.28B

P/E ratio (trailing)

-5.22

P/E ratio (forward)

-5.73

EPS (trailing)

-2.50

EPS (forward)

-2.28

PEG ratio

n/a

Price to book

3.67

Revenue growth

-37.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.27

Employees

312

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Generate Biomedicines, Inc. and compare it with other stocks.